Erratum: At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody (Scientific Reports (2016) 6 (20029) DOI: 10.1038/srep20029);At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody

Scientific Reports

Volumn 7, Issue , 2016, Pages

  Yu, Chuanfei ^a   Gao, Kai ^a   Zhu, Lei ^a,b   Wang, Wenbo ^a   Wang, Lan ^a   Zhang, Feng ^a   Liu, Chunyu ^a   Li, Meng ^a   Wormald, Mark R ^c   Rudd, Pauline M ^d,e   Wang, Junzhi ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d National Institute for Bioprocessing   (Ireland)

^e AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GALACTOSE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; OLIGOSACCHARIDE; POLYSACCHARIDE;

ANIMAL; BIOSYNTHESIS; CARBOHYDRATE ANALYSIS; HUMAN; IMMUNOLOGY; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARBOHYDRATE SEQUENCE; EPITOPES; GALACTOSE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; OLIGOSACCHARIDES; POLYSACCHARIDES;

EID: 84956696215     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46385     Document Type: Erratum

References (51)

1. Aggarwal, R. S. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol. 32, 32-39 (2014).
2. Zheng, K., Yarmarkovich, M., Bantog, C., Bayer, R., Patapoff, T. W. Influence of glycosylation pattern on the molecular properties of monoclonal antibodies. MAbs. 6, 649-658 (2014).
3. Raju, T. S., Lang, S. E. Diversity in structure and functions of antibody sialylation in the Fc. Curr Opin Biotechnol. 30, 147-152 (2014).
4. Read, E. K., Park, J. T., Brorson, K. A. Industry and regulatory experience of the glycosylation of monoclonal antibodies. Biotechnol Appl Biochem. 58, 213-219 (2011).
5. Ghaderi, D., Zhang, M., Hurtado-Ziola, N., Varki, A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev. 28, 147-175 (2012).
6. Bosques, C. J. et al. Chinese hamster ovary cells can produce galactose-alpha-1,3-galactose antigens on proteins. Nat Biotechnol. 28, 1153-1156 (2010).
7. Borys, M. C. et al. Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol Bioeng. 105, 1048-1057 (2010).
8. Lammerts van Bueren, J. J. et al. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 29, 574-576 (2011).
9. Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., Varki, A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 28, 863-867 (2010).
10. Koike, C. et al. Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci USA 104, 559-564 (2007).
11. Chou, H. H. et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 95, 11751-11756 (1998).
12. Chung, C. H. et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 358, 1109-1117 (2008).
13. Takashima, S. Characterization of mouse sialyltransferase genes: their evolution and diversity. Biosci Biotechnol Biochem. 72, 1155-1167 (2008).
14. Byrne, B., Donohoe, G. G., O'Kennedy, R. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov Today. 12, 319-326 (2007).
15. Raju, T. S., Briggs, J. B., Borge, S. M., Jones, A. J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology. 10, 477-486 (2000).
16. Hedlund, M. et al. N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol Cell Biol. 27, 4340-4346 (2007).
17. Samraj, A. N., Laubli, H., Varki, N., Varki, A. Involvement of a non-human sialic Acid in human cancer. Front Oncol. 4, 33 (2014).
18. Eleftheriou, P. et al. Prevalence of anti-Neu5Gc antibodies in patients with hypothyroidism. Biomed Res Int. 2014, 963230 (2014).
19. Ng, P. S. et al. Ferrets exclusively synthesize Neu5Ac and express naturally humanized influenza A virus receptors. Nat Commun. 5, 5750 (2014).
20. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 8, 226-234 (2009).
21. Janin-Bussat, M. C. et al. Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. Methods Mol Biol. 988, 93-113 (2013).
22. Padler-Karavani, V. et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology. 18, 818-830 (2008).
23. Schiestl, M. et al. The role of the quality assessment in the determination of overall biosimilarity: a simulated case study exercise. Biologicals. 42, 128-132 (2014).
24. Cingoz, O. Ustekinumab. MAbs. 1, 216-221 (2009).
25. Poole, R. M., Vaidya, A. Ramucirumab: first global approval. Drugs. 74, 1047-1058 (2014).
26. Yamamoto, K. Microbial endoglycosidases for analyses of oligosaccharide chains in glycoproteins. J Biochem. 116, 229-235 (1994).
27. Kaneko, Y., Nimmerjahn, F., Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 313, 670-673 (2006).
28. Anthony, R. M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 320, 373-376 (2008).
29. Stadlmann, J. et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics. 9, 4143-4153 (2009).
30. Stadlmann, J., Pabst, M., Altmann, F. Analytical and Functional Aspects of Antibody Sialylation. J Clin Immunol. 30 (Suppl 1), S15-S19 (2010).
31. Dick, L. W. Jr., Qiu, D., Mahon, D., Adamo, M., Cheng, K. C. C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes. Biotechnol Bioeng. 100, 1132-1143 (2008).
32. Vlasak, J., Ionescu, R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol. 9, 468-481 (2008).
33. Watanabe, T., Inoue, N., Kutsukake, T., Matsuki, S., Takeuchi, M. Labeling conditions using a 2-aminobenzamide reagent for quantitative analysis of sialo-oligosaccharides. Biol Pharm Bull. 23, 269-273 (2000).
34. Jahn, E. M., Schneider, C. K. How to systematically evaluate immunogenicity of therapeutic proteins-regulatory considerations. N Biotechnol. 25, 280-286 (2009).
35. Kavai, M., Szegedi, G. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. Autoimmun Rev. 6, 497-502 (2007).
36. Glovsky, M. M., Ward, P. A., Johnson, K. J. Complement determinations in human disease. Ann Allergy Asthma Immunol. 93, 513-522; quiz 523-515, 605 (2004).
37. Bayon, Y., Alonso, A., Hernandez, M., Nieto, M. L., Sanchez Crespo, M. Mechanisms of cell signaling in immune-mediated inflammation. Cytokines Cell Mol Ther. 4, 275-286 (1998).
38. Rojko, J. L. et al. Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes: Review and Case Studies. Toxicol Pathol. 42, 725-764 (2014).
39. de la Luz-Hernandez, K. et al. Cancer vaccine characterization: from bench to clinic. Vaccine. 32, 2851-2858 (2014).
40. Horwacik, I., Rokita, H. Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis. Apoptosis. 20, 679-688 (2015).
41. Dalziel, M., McFarlane, I., Axford, J. S. Lectin analysis of human immunoglobulin G N-glycan sialylation. Glycoconj J. 16, 801-807 (1999).
42. Krapp, S., Mimura, Y., Jefferis, R., Huber, R., Sondermann, P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol. 325, 979-989 (2003).
43. Noguchi, A., Mukuria, C. J., Suzuki, E., Naiki, M. Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J Biochem. 117, 59-62 (1995).
44. Xu, X. et al. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat Biotechnol. 29, 735-741 (2011).
45. Chenu, S. et al. Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy. Biochim Biophys Acta. 1622, 133-144 (2003).
46. Bergwerff, A. A. et al. Variation in N-linked carbohydrate chains in different batches of two chimeric monoclonal IgG1 antibodies produced by different murine SP2/0 transfectoma cell subclones. Glycoconj J. 12, 318-330 (1995).
47. Montesino, R. et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody Nimotuzumab through process development. Biologicals. 40, 288-298 (2012).
48. Ghaderi, D., Zhang, M., Hurtado-Ziola, N., Varki, A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev. 28, 147-175.
49. Muchmore, E. A., Milewski, M., Varki, A., Diaz, S. Biosynthesis of N-glycolyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool. J Biol Chem. 264, 20216-20223 (1989).
50. Raymond, C. et al. Production of alpha2,6-sialylated IgG1 in CHO cells. MAbs. 7, 571-583 (2015).
51. Lauber, M. A. et al. Rapid Preparation of Released N-Glycans for HILIC Analysis Using a Labeling Reagent that Facilitates Sensitive Fluorescence and ESI-MS Detection. Anal Chem. 87, 5401-5409 (2015).